Translational study identifies XPF and MUS81 as predictive biomarkers for oxaliplatin-based peri-operative chemotherapy in patients with esophageal adenocarcinoma

Oxaliplatin-based chemotherapy is used to treat patients with esophageal adenocarcinoma (EAC), but no biomarkers are currently available for patient selection. We performed a prospective, clinical trial to identify potential biomarkers associated with clinical outcomes. Tumor tissue was obtained fro...

Descripción completa

Detalles Bibliográficos
Autores principales: MacGregor, T. P., Carter, R., Gillies, R. S., Findlay, J. M., Kartsonaki, C., Castro-Giner, F., Sahgal, N., Wang, L. M., Chetty, R., Maynard, N. D., Cazier, J. B., Buffa, F., McHugh, P. J., Tomlinson, I., Middleton, M. R., Sharma, R. A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5940885/
https://www.ncbi.nlm.nih.gov/pubmed/29739952
http://dx.doi.org/10.1038/s41598-018-24232-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5940885/
https://www.ncbi.nlm.nih.gov/pubmed/29739952
http://dx.doi.org/10.1038/s41598-018-24232-2

Ejemplares similares